AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24807889 — intervention group
Group type: EXPERIMENTAL
Intervention: VTX-2337 (0.1-3.9 mg/m(2)) administered subcutaneously on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 33
Study 24808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake with a higher protein:energy ratio at days 10 and 21
Number of subjects: 141
Study 24808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid treatment
Number of subjects: 141
Study 24808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial growth and quality of nutrition
Number of subjects: 141
Study 24808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational and postnatal ages
Number of subjects: 141
Study 24808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth between birth and day 5 and growth between day 5 and discharge
Number of subjects: 141
Study 24808483 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FFM with reference data in term infants
Number of subjects: 141
Study 24809540 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for occlusal caries in adult patients
Number of subjects: 282
Study 24809540 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention for occlusal caries in pediatric patients
Number of subjects: 282
Study 24809761 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate CRF
Number of subjects: 423
Study 24809761 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRF
Number of subjects: 423
Study 24809761 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRF after adjustment for MVPA
Number of subjects: 423
Study 24809761 — intervention group
Group type: COMPARATOR
Intervention: Low CRF
Number of subjects: 423
Study 24809761 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 423
Study 24811751 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (0.25 mg BID, 0.5 mg BID, 1 mg BID)
Number of subjects: 277
Study 24811751 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum CA of 4 to 6 weeks
Number of subjects: 277
Study 24811751 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 21-34 years
Number of subjects: 277
Study 24811751 — intervention group
Group type: EXPERIMENTAL
Intervention: MNWS urge to smoke score of 2 to 4
Number of subjects: 277
Study 24811751 — intervention group
Group type: EXPERIMENTAL
Intervention: Having made ≥ 1 serious quit attempts
Number of subjects: 277
Study 24811754 — intervention group
Group type: EXPERIMENTAL
Intervention: SC serum-free interferon β-1a 44 μg or 22 μg 3 times weekly for 12 months
Number of subjects: 251
Study 24811995 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 204
Study 24811995 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's Disease (CD)
Number of subjects: 204
Study 24811995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis (UC)
Number of subjects: 204
Study 24811995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouchitis
Number of subjects: 204
Study 24812403 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) containing about 25% mutation-specific polyfunctional T(H)1 cells
Number of subjects: 1
Study 24812403 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with >95% pure population of mutation-reactive T(H)1 cells
Number of subjects: 1
Study 24812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-positive men
Number of subjects: 9342
Study 24812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-negative men
Number of subjects: 9342
Study 24812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-positive men (PCR-based studies)
Number of subjects: 9342
Study 24812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-negative men (PCR-based studies)
Number of subjects: 9342
Study 24813429 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the testlet response model (TRM)
Number of subjects: 753
Study 24813429 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the constrained graded response model (CGRM)
Number of subjects: 753
Study 24813429 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the unconstrained graded response model (UGRM)
Number of subjects: 753
Study 24813429 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-QOL total score
Number of subjects: 753
Study 24814215 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 52
Study 24814215 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 healthy full-term infants)
Number of subjects: 52
Study 24814497 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical classification of AF (paroxysmal or persistent) by physicians at baseline
Number of subjects: 1195
Study 24814497 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ejection fraction
Number of subjects: 1195
Study 24814497 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of coronary artery disease
Number of subjects: 1195
Study 24814582 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme
Number of subjects: 0
Study 24814620 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix©)
Number of subjects: 271
Study 24814620 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide (ALU group)
Number of subjects: 271
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky driving (hostile, reckless, and drinking and driving)
Number of subjects: 312
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 312
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduct behaviour problems after age 15
Number of subjects: 312
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem drinking
Number of subjects: 312
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and conduct behaviour problems before age 15
Number of subjects: 312
Study 24814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (males)
Number of subjects: 312
Study 24814743 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, validated questionnaire on functional impairments and QoL administered at diagnosis and after one, two, and five years.
Number of subjects: 1500
Study 24814759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 8790
Study 24814759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 8790
Study 24814759 — intervention group
Group type: COMPARATOR
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 8790
Study 24814917 — intervention group
Group type: EXPERIMENTAL
Intervention: Complaint categories established from patient admissions
Number of subjects: 9863
Study 24815803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months follow-up
Number of subjects: 821
Study 24815803 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months follow-up
Number of subjects: 821
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/d
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/d
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/d
Number of subjects: 3570
Study 24816198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (all doses combined)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (elderly, all doses combined)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (elderly)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (maintenance)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (open-label stabilization period)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (randomized period)
Number of subjects: 3570
Study 24816198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (randomized period)
Number of subjects: 3570
Study 24816240 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring minimal residual disease (MRD) using quantitative real-time polymerase chain reaction (qPCR) after induction therapy.
Number of subjects: 158
Study 24816240 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutation ratio cut-off of 0.01 after induction therapy.
Number of subjects: 158
Study 24816240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse after 2 years for patients with NPM1 ratios above the cut-off.
Number of subjects: 158
Study 24816240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse after 2 years in the favorable subgroup according to European LeukemiaNet.
Number of subjects: 158
Study 24816856 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat (50 or 100 mg) self-administered orally twice daily
Number of subjects: 19
Study 24816908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ganitumab (18 mg/kg) and conatumumab (15 mg/kg)
Number of subjects: 78
Study 24816908 — intervention group
Group type: COMPARATOR
Intervention: Ganitumab alone
Number of subjects: 78
Study 24816908 — intervention group
Group type: COMPARATOR
Intervention: Conatumumab alone
Number of subjects: 78
Study 24817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to both quadriceps for 45 minutes at a stimulation frequency of 50 Hz
Number of subjects: 20
Study 24817528 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 20
Study 24817603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg BiD for 5 days every week) + Bevacizumab (5 mg/kg intravenously every 14 days)
Number of subjects: 14
Study 24817603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib + Bevacizumab
Number of subjects: 14
Study 24819055 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-microsphere SPECT/CT imaging
Number of subjects: 14
Study 24819055 — intervention group
Group type: COMPARATOR
Intervention: (166)Ho-microsphere planar scintigraphy
Number of subjects: 14
Study 24819055 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-MAA SPECT/CT imaging
Number of subjects: 14
Study 24819055 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-MAA planar scintigraphy
Number of subjects: 14
Study 24819148 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of C9ORF72 mutation
Number of subjects: 0
Study 24819148 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers
Number of subjects: 0
Study 24819256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 346
Study 24819256 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity risk allele at FTO SNP rs9939609
Number of subjects: 346
Study 24819395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10mg and melphalan 2mg for 21 days/28
Number of subjects: 20
Study 24819685 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-31121 at 300 mg BID
Number of subjects: 30
Study 24819685 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-31121 at 350 mg BID
Number of subjects: 30
Study 24819685 — intervention group
Group type: EXPERIMENTAL
Intervention: OPB-31121-related adverse events
Number of subjects: 30
Study 24819685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of OPB-31121
Number of subjects: 30
Study 24819685 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcome
Number of subjects: 30
Study 24819684 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + 5-FU/LV
Number of subjects: 36
Study 24819684 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + mFOLFOX6
Number of subjects: 36
Study 24819684 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + mFOLFOX6 + panitumumab
Number of subjects: 36
Study 24819684 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus + 5-FU/LV + mFOLFOX6
Number of subjects: 36
Study 24820045 — intervention group
Group type: COMPARATOR
Intervention: CRVPP in controls
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVPP in early glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVPP in moderate glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVPP in advanced glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: COMPARATOR
Intervention: OPP1 in controls
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP1 in early glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP1 in moderate glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP1 in advanced glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: COMPARATOR
Intervention: OPP2 in controls
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP2 in early glaucoma
Number of subjects: 34
Study 24820045 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP2 in moderate glaucoma
Number of subjects: 34
Study 24820437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pulses (beans, peas, chickpeas, lentils)
Number of subjects: 9
Study 24820437 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric controls
Number of subjects: 9
Study 24821352 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 737
Study 24821357 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent IPV victimization
Number of subjects: 203
Study 24821356 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoid (SC) products
Number of subjects: 42
Study 24821356 — intervention group
Group type: COMPARATOR
Intervention: Current marijuana and tobacco use
Number of subjects: 42
Study 24821713 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1b (IFNβ-1b) during pregnancy
Number of subjects: 99
Study 24821881 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC)
Number of subjects: 44
Study 24821883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with pegfilgrastim support
Number of subjects: 39
Study 24821883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ddMVAC
Number of subjects: 39
Study 24823514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 950
Study 24823675 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia (defined as haemoglobin <12 g/dL for women and <13 g/dL for men)
Number of subjects: 929
Study 24823675 — intervention group
Group type: COMPARATOR
Intervention: Non-anaemic patients
Number of subjects: 929
Study 24823675 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 929
Study 24824628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8 for up to 8 cycles
Number of subjects: 64
Study 24824628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (GP)
Number of subjects: 64
Study 24824852 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose-intensified cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (80 mg/m²) regimen for eight cycles
Number of subjects: 29
Study 24824852 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose-intensified cisplatin, epirubicin, and paclitaxel regimen
Number of subjects: 29
Study 24825411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg once daily (days 1-5 and 12-16)
Number of subjects: 28
Study 24825411 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg/ritonavir 100 mg once daily (days 6-16)
Number of subjects: 28
Study 24825411 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir
Number of subjects: 28
Study 24825411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 28
Study 24825563 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) of resting oxygen saturation (Spo2) in COPD populations.
Number of subjects: 4368
Study 24826798 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib added to endocrine therapy
Number of subjects: 11
Study 24827131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184)
Number of subjects: 25
Study 24827135 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) combined with FEC100 (5-fluorouracil 500 mg/m², epidoxorubicin 100 mg/m², cyclophosphamide 500 mg/m²) followed by docetaxel (100 mg/m²), administered for eight cycles q.3 weeks and four cycles of FEC100 q.3 weeks, followed by four cycles of docetaxel q.3 weeks.
Number of subjects: 60
Study 24827135 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab in combination with FEC100 followed by docetaxel
Number of subjects: 60
Study 24828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Alleviating manoeuvres (AM) used by 138 patients
Number of subjects: 154
Study 24828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch (sensory trick)
Number of subjects: 154
Study 24828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or location of AM
Number of subjects: 154
Study 24828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors of effective AM
Number of subjects: 154
Study 24829202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 6-mercaptopurine (6MP)
Number of subjects: 298
Study 24829343 — intervention group
Group type: EXPERIMENTAL
Intervention: RV144 HIV-1 vaccine
Number of subjects: 0
Study 24829343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24829444 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anaemia (severe and moderate)
Number of subjects: 39309
Study 24829444 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 39309
Study 24829444 — intervention group
Group type: COMPARATOR
Intervention: Normal preoperative Hb concentrations
Number of subjects: 39309
Study 24829492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month fish-oil supplementation providing 1.4 g DHA/d plus 1.8 g EPA/d
Number of subjects: 34
Study 24829746 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg CEA peptide (Arm A)
Number of subjects: 19
Study 24829746 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg CEA peptide (Arm B)
Number of subjects: 19
Study 24829746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg CEA peptide (Arm C)
Number of subjects: 19
Study 24829746 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 24829756 — intervention group
Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine at 1.5 mg dose
Number of subjects: 24
Study 24829756 — intervention group
Group type: COMPARATOR
Intervention: pINGmuTyr vaccine at 0.2 mg and 0.5 mg doses
Number of subjects: 24
Study 24829756 — intervention group
Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine
Number of subjects: 24
Study 24829756 — intervention group
Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine followed by ipilimumab
Number of subjects: 24
Study 24829759 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin 21 (IL-21) plus sorafenib (400 mg twice daily)
Number of subjects: 52
Study 24830339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Number of subjects: 0
Study 24830339 — intervention group
Group type: EXPERIMENTAL
Intervention: Free combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Number of subjects: 0
Study 24831647 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 27
Study 24831720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelash line resection
Number of subjects: 24
Study 24831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg oral on days 1-14) plus R-CHOP21 (375 mg/m² rituximab, 750 mg/m² cyclophosphamide, 50 mg/m² doxorubicin, 1.4 mg/m² vincristine on day 1, and 40 mg/m² prednisone on days 1-5)
Number of subjects: 49
Study 24831981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus R-CHOP21
Number of subjects: 49
Study 24834795 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every four weeks, with additional doses on study days 8 and 15.
Number of subjects: 271
Study 24835462 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 19
Study 24835828 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG IUS)
Number of subjects: 11
Study 24836083 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-D6
Number of subjects: 2242
Study 24836083 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-C6
Number of subjects: 2242
Study 24836083 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-D6 and IDS-C6
Number of subjects: 2242
Study 24836083 — intervention group
Group type: COMPARATOR
Intervention: HAM-D17
Number of subjects: 2242
Study 24836083 — intervention group
Group type: COMPARATOR
Intervention: IDS-C30
Number of subjects: 2242
Study 24836963 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETV) plus two active NRTIs
Number of subjects: 287
Study 24836963 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETV) (once or twice daily)
Number of subjects: 287
Study 24839031 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg subcutaneous monthly for 6 months
Number of subjects: 3280
Study 24839031 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 3280